Amiodarone and SARS-CoV-2 infection/COVID-19: UTILITY?
PDF (Español (España))

How to Cite

1.
Abuabara-Franco E, Bohórquez-Rivero J, Sáenz-López J, Restom-Arrieta J, Uparella-Gulfo I. Amiodarone and SARS-CoV-2 infection/COVID-19: UTILITY?. Rev. Colomb. Nefrol. [Internet]. 2020 Jun. 30 [cited 2022 Jun. 26];7(Supl.2). Available from: https://revistanefrologia.org/index.php/rcn/article/view/446
https://doi.org/10.22265/acnef.7.Supl.2.446
PDF (Español (España))

References

Abuabara-Franco E, Bohórquez-Rivero J, Restom-Arrieta J, Sáenz-López J, Correa-Guerero J, Mendoza-Paternina C. Consideraciones actuales de antimaláricos en la infección por SARS-CoV-2 y su impacto. Rev. Colomb. Nefrol; 2020 [citado 2020 Jul];7(Supl.2). Disponible en: https://revistanefrologia.org/index.php/rcn/article/view/406.

Aimo A, Baritussio A, Emdin M, Tascini C. Amiodarone as a possible therapy for coronavirus infection. Eur J Prev Cardiol. 2020. https://doi.org/10.1177/2047487320919233.

Stadler K, Ha HR, Ciminale V, Spirli C, Saletti G, Schiavon M, et al. Amiodarone alters late endosomes and inhibits SARS coronavirus nfection at a post-endosomal level. Am J Respir Cell Mol Biol. 2008;39(2):142-9. https://doi.org/10.1165/rcmb.2007-0217OC.

Guo Y, Cao Q, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Mil Med Res. 2020;7(1):11. https://doi.org/10.1186/s40779-020-00240-0

Wang L, Wang Y, Ye D, Liu Q. A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence. Int J Antimicrob Agents; 2020;55(6):105948. https://doi.org/10.1016/j.ijantimicag.2020.105948.

Sohrabi C, Alsafi Z, O’Neill N, Khan M, Kerwan A, Al-Jabir A, et al. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). Int J Surg. 2020;76:71-6. https://doi.org/10.1016/j.ijsu.2020.02.034.

Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrobl Agents. 2020;55(5):105938. https://doi.org/10.1016/j.ijantimicag.2020.105938.

Adhikari SP, Meng S, Wu YJ, Mao YP, Ye RX, Wang QZ, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Poverty. 2020;9(1):29 https://doi.org/10.1186/s40249-020-00646-x.

Mousavizadeh L, Ghasemi S. Genotype and phenotype of COVID-19: Their roles in pathogenesis. J Microbiol Immunol Infect. 2020. https://doi.org/10.1016/j.jmii.2020.03.022.

. Fantini J, Di Scala C, Chahinian H, Yahi N. Structural and molecular modeling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. Int J Antimicrob Agents. 2020;55(5):105960. https://doi.org/10.1016/j.ijantimicag.2020.105960 .

Gehring G, Rohrmann k, Atenchong N, Mittler E, Becker S, Dahlmann F, et al. The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry. J Antimicrob Chemother. 2014;69(8):2123-31. https://doi.org/10.1093/jac/dku091.

Bohorquez-Rivero JJ, Alvear.Orózco AS, Rivera-Moreno MM, Rivera.Moreno E, Restom-Arrieta JG. Amiodarona y su Papel en la Disfunción Tiroidea: La Importancia del Conocimiento y Seguimiento. Archivos de Medicina. 2019;15:4(6). https://doi.org/10.3823/1420.

Perico L, Benigni A, Remuzzi G. Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade. Nephron. 2020;144:213-21. https://doi.org/10.1159/000507305.

Rali AS, Sauer AJ. COVID-19 Pandemic and Cardiovascular Disease. US CardiologyReview. 2020;14:E01.

https://doi.org/10.15420/usc.2020.14.

No national or foreign publication may partially or totally reproduce or translate Revista Colombiana de Nefrología articles or abstracts without prior written permission from the journal’s Editorial Board.

Dimensions


PlumX


Downloads

Download data is not yet available.